- “Advancing Ayurveda Through Ethnobiology Drug Development”
- Topics Include Mateon’s ARTIShield™ for the Treatment of COVID-19 and COVID-19/Influenza Coinfection
The symposium will take place on
“COVID-19 requires that we leverage the totality of our medical knowledges. Ayurveda is a form of traditional Indian medicine codified in ancient Sanskrit texts with a vast and rich resource of safe and effective treatments,” said
Presenters include luminaries from multiple dimensions of the Ayurveda universe; scientists, physicians, ethnobotanists and ministry representatives.
“We are now entering the flu season and with the emergence of SARS-CoV-2/Influenza coinfection, the availability of ArtiShieldTM as a potentially effective agent against both will be instrumental in stopping this pandemic,” said Dr.
C.K. Katiyar, PhD, MD (Ayurveda), Chief Executive Officer-Technical, Emami Ltd.
- JLN Sastry, BAMS, MD, PhD (Ayurveda); CEO, National Medicinal
Plant Board– AYUSH Ministry
Shekhar Annambhotla, BAMS, MD Founder of Ayurveda Wellness Center- Ojas, LLC,
Suhas Kshirsagar, Director of Ayurvedic Healing Inc., Advisor to Chopra Center
Balram Singh, PhD, Professor and President at Institute of Advanced Sciences, Dartmouth, MA, Prime Bio, Inc
Vuong Trieu, CEO Mateon Therapeutics Saran Saund, CBO Mateon Therapeutics
- Hitesh Windlas, Founder and Managing Director of
Windlas Biotech Pvt Ltd.
Ravikumar Reddy, CSO, Sri Sri Tattva. BAMS. Participant Ministry of AYUSH, Export promotion council.
ARTIShield ™- an Ethnobiology Drug
Mateon is pursuing several avenues with respect to the development and commercialization of ARTIShieldTM in the treatment of COVID-19. ARTIShield™ is Ayurveda - Dvipaantara Damanaka - and is labeled as a capsule containing Artemisia Powder 500mg. It is a demonstration of how Ethnobiology can be used to drive drug development against emerging pandemics.
The classical pharmaceutical regulatory pathways have failed to provide fast-track to treatment and vaccines. Government resources have concentrated on a few candidates most of which have failed. The Ayurvedic medicine route is proving to be an accelerated pathway to deploy a well-known, abundantly available and cost effective Ayurvedic medicine that is safe and being proven in-vitro and large-scale clinical trial to be effective.
ARTIShield ™ - Commercialization in
Mateon announced that ARTIShield™ has been approved for manufacture and marketing by the Ministry of AYUSH (Ayurveda, Yoga and Naturopathy, Unani, Siddha and Homoeopathy) in
ARTI-19 Multi-national Phase IV Trial, Currently in
Mateon announced the enrollment of its first patient in a Phase IV study ARTI-19, “A Prospective, Randomized, Multi-center, Open label, Interventional Study to Evaluate the Safety and Efficacy of Artemisinin 500 mg capsule in Treatment of Adult Subjects with COVID-19”. This trial will compare the efficacy of oral doses with standard-of-care (SOC) versus SOC alone. This is a global study with India to contribute at least 300 patients to the total aggregate of 3000 patients. We expect preliminary top-line data for ARTI-19 sometime in the near future.
Mateon was created by the recent reverse merger with Oncotelic, which became a wholly owned subsidiary of Mateon, thereby creating an immuno-oncology company dedicated to the development of first in class RNA therapeutics as well as small molecule drugs against cancer and infectious diseases. OT-101, the lead immuno-oncology drug candidate of Mateon/Oncotelic, is a first-in-class anti-TGF-βRNA therapeutic that exhibited single agent activity in some relapsed/refractory cancer patients in clinical trial settings. OT-101 also has activity against SARS-CoV-2. Mateon/Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers. Mateon has rare pediatric designation for DIPG (OT-101), melanoma (CA4P), and AML (OXi4503).
Mateon's Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as “may”, “expect”, “anticipate” “hope”, “vision”, “optimism”, “design”, “exciting”, “promising”, “will”, “conviction”, "estimate," "intend," "believe", “quest for a cure of cancer”, “innovation-driven”, “paradigm-shift”, “high scientific merit”, “impact potential” and similar expressions are intended to identify forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about future plans, the progress, timing, clinical development, scope and success of future clinical trials, the reporting of clinical data for the company’s product candidates and the potential use of the company’s product candidates to treat various cancer indications. Each of these forward-looking statements involves risks and uncertainties and actual results may differ materially from these forward-looking statements. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. These risks are not exhaustive, the company faces known and unknown risks, including the risk factors described in the company’s annual report on Form 10-K filed with the
Source: Mateon Therapeutics, Inc.